OBD is a pioneer in the rapidly advancing field of 3D genomics, with a clinically proven platform and a robust intellectual property portfolio. OBD has established itself as a key player in the diagnostics sector, offering groundbreaking tests with direct clinical applications. Central to its offerings is the EpiSwitch® platform, which is clinically validated and provides revolutionary diagnostic tools for cancer and other complex diseases. A new offering, Orion can act as a portal to the EpiSwitch platform, enabling researchers access and infer 3D regulatory structure from sequence. With validated tests for prostate cancer (PSE), immune therapy response (CiRT) and pipeline tests attracting interest, especially for ME/CFS, OBD is well-positioned for substantial growth, with ongoing discussions aimed at securing additional third-party funding and strategic partnerships. With a scalable business model and a focus on sustained month-over-month growth, OBD is poised for expansion into key markets. We initiate coverage with a BUY recommendation and a target price of 1.0p.
